Toll Free: 1-888-928-9744

Poxvirus Infections - Pipeline Review, H1 2016

Published: Mar 30, 2016 | Pages: 39 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Poxvirus Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Poxvirus Infections - Pipeline Review, H1 2016', provides an overview of the Poxvirus Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Poxvirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poxvirus Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Poxvirus Infections
- The report reviews pipeline therapeutics for Poxvirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Poxvirus Infections therapeutics and enlists all their major and minor projects
- The report assesses Poxvirus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Poxvirus Infections

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Poxvirus Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Poxvirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Poxvirus Infections Overview 6 Therapeutics Development 7 Pipeline Products for Poxvirus Infections - Overview 7 Pipeline Products for Poxvirus Infections - Comparative Analysis 8 Poxvirus Infections - Therapeutics under Development by Companies 9 Poxvirus Infections - Therapeutics under Investigation by Universities/Institutes 10 Poxvirus Infections - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Poxvirus Infections - Products under Development by Companies 13 Poxvirus Infections - Products under Investigation by Universities/Institutes 14 Poxvirus Infections - Companies Involved in Therapeutics Development 15 China Biologic Products, Inc. 15 SIGA Technologies, Inc. 16 Poxvirus Infections - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 Antibody for Poxvirus Infections - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Monoclonal Antibodies for Infectious Disease - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecule to Inhibit DNA Synthesis for Poxvirus and Herpes Infections - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 tecovirimat - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 varicella hyperimmune globulins - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Poxvirus Infections - Recent Pipeline Updates 33 Poxvirus Infections - Dormant Projects 36 Poxvirus Infections - Product Development Milestones 37 Featured News & Press Releases 37 Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral 37 Mar 12, 2013: Siga Delivers First Courses Of Arestvyr To US Strategic National Stockpile Under BARDA Contract 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
Number of Products under Development for Poxvirus Infections, H1 2016 7 Number of Products under Development for Poxvirus Infections - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Poxvirus Infections - Pipeline by China Biologic Products, Inc., H1 2016 15 Poxvirus Infections - Pipeline by SIGA Technologies, Inc., H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 21 Number of Products by Stage and Route of Administration, H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 25 Poxvirus Infections Therapeutics - Recent Pipeline Updates, H1 2016 33 Poxvirus Infections - Dormant Projects, H1 2016 36


List of Figures
Number of Products under Development for Poxvirus Infections, H1 2016 7 Number of Products under Development for Poxvirus Infections - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Targets, H1 2016 18 Number of Products by Stage and Targets, H1 2016 18 Number of Products by Mechanism of Actions, H1 2016 20 Number of Products by Stage and Mechanism of Actions, H1 2016 20 Number of Products by Routes of Administration, H1 2016 22 Number of Products by Stage and Routes of Administration, H1 2016 22 Number of Products by Molecule Types, H1 2016 24 Number of Products by Stage and Molecule Types, H1 2016 24

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the i

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify